GENE ONLINE|News &
Opinion
Blog

2021-08-02| SpecialTechnology

BIO Asia 2021 Highlights: Realizing The Promise of Cell and Gene Therapies

by Kathy Huang
Share To
The cell and gene therapy market is booming with several global companies advancing their latest innovations to Phase 2 and late-stage trials.

At the regulatory level, although only a handful of products have been approved hitherto, the FDA expects to review close to 10 to 20 cell and gene therapy IND applications each year by 2025. At this juncture, the industry is striving to strike a balance between a continuous flow of innovations and streamline existing candidates within the manufacturing, regulatory and policy climate of prevailing frameworks. In a BIO Asia-Taiwan session, experts from big pharma, regulatory affairs, and academia discussed the current developments in the field, besides its potential and challenges for the future.

It's free! Log in now to read

LATEST
Should People Looking to Lose Weight Skip Sugar Substitutes?
2023-05-30
Advancing Next-Generation Cancer Metabolic Therapy by Targeting Critical Amino Acid Metabolic Pathways: An Interview with Brian A. Van Tine, MD, PhD
2023-05-26
Rona Therapeutics, Keymed Biosciences Team Up To Develop siRNA Drugs For Kidney Disease
2023-05-25
CDC Calls an End to J&J’s COVID-19 Vaccine in the U.S.
2023-05-25
A Close Look at the Evolution of ESG in Biopharma
2023-05-22
Scientists Identified Potential New Drugs to Combat Blindness
2023-05-21
FDA Approves Astellas’ Non-hormonal Menopause Treatment After Extended Review
2023-05-19
EVENT
2023-05-16
The 2nd International Healthcare Week
Hong Kong , China
2023-06-02
2023 ASCO annual meeting
Chicago, USA
2023-07-26
BIO Asia-Taiwan 2023
Taipei, Taiwan
2023-09-06
2023 Bio Asia Pacific
Bangkok, Thailand
Scroll to Top